leisure time -WSS

leisure time

author：entertainment 2025-09-30 22:03:55 - browse：61912

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA approves world's first CRISPR

leisure time

WSS

People with mental disorders often marry others with same

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

SCOTUS to consider access to abortion pill mifepristone

Young boy dies in trial for Pfizer Duchenne gene therapy

Insurer loopholes limit power of law against surprise medical bills

FDA approves world's first CRISPR

leisure time

leisure time

leisure time

New air purifier tech could be key to improving indoor air quality

Researchers test human milk's ability to repair gut microbiome

Guidelines to prevent youth baseball injuries need more muscle

Young boy dies in trial for Pfizer Duchenne gene therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

23andMe had bad news about my health. I wish a person had delivered it

Patients' immediate access to test results puts radiologists in a bind

At least 13 dead in Texas as scorching temps continue

Americans' trust in science, scientist continues decline: Report

hotspot

Young boy dies in trial for Pfizer Duchenne gene therapy

Why sickle cell disease is getting the first CRISPR treatment

Republican states more likely to report Covid vaccine side effects

Four alarming medical procedures we’re glad history forgot

Harvard scientists, with Google, unveil the most detailed brain map ever

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Wikipedia

leisure time

leisure time

knowledge